<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00715702</url>
  </required_header>
  <id_info>
    <org_study_id>D1710C00020</org_study_id>
    <secondary_id>EudraCt nr 2007-007541-</secondary_id>
    <nct_id>NCT00715702</nct_id>
  </id_info>
  <brief_title>Safety Study of AZD5672 in Renally Impaired Subjects</brief_title>
  <official_title>An Open-Label, Single-Centre, Parallel Group, Phase I Study To Compare the Pharmacokinetics of AZD5672 Single Dose in Patients With Renal Impairment and Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the pharmacokinetics of a single dose of AZD5672
      in patients with renal impairment by comparing with healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK variables</measure>
    <time_frame>Frequent sampling occasions during study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety variables (adverse events, blood pressure, pulse, safety lab)</measure>
    <time_frame>During the treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Moderate renal impairment and matched volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Mild or Severe renal impairment and matched volunteers. Type of patient group determined after safety review of 1st group data</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5672</intervention_name>
    <description>100 mg oral single dose</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed written informed consent.

          -  Females should not be of childbearing potential

          -  Subjects classified as renally impaired should have been stable (in the Investigator's
             opinion) for at least 3 months prior to Visit 1.

        Exclusion Criteria:

          -  Patients taking prescription of medications: Pgp substrates, inhibitors and /or
             inducers, medications that affect creatinine clearance(within 7 days of dosing),
             atorvastatin &gt;20mg once daily, medications that prolong QT/QTc interval

          -  Change in dose regimen of prescribed medication and NSAIDs within the 2 weeks before
             enrolment (renal patients only)

          -  Participation in another clinical study involving administration of an investigational
             product in the 3 months prior to treatment (or within 5 half-lives of the last dose of
             the investigational product, whichever is longer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rod Hepburn</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, Charnwood, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angelika Weil</last_name>
    <role>Principal Investigator</role>
    <affiliation>APEX GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>MÃ¼nchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2008</study_first_submitted>
  <study_first_submitted_qc>July 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2008</study_first_posted>
  <last_update_submitted>April 28, 2009</last_update_submitted>
  <last_update_submitted_qc>April 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mark Layton, MD, PhD, Medical Science Director</name_title>
    <organization>AstraZeneca R&amp;D Alderely Park</organization>
  </responsible_party>
  <keyword>AZD5672</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-(1-(3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-methanesulfonylphenyl)acetamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

